Table 5.

Side effects and adverse reactions

Answer options	Percentage (n)
None	64.1 (50)
Antibodies to infliximab	17.9 (14)
Infusion reaction or delayed hypersensitivity reaction	16.7 (13)
Worsening ulcerative colitis	14.1 (11)
Infection	12.8 (10)
Headache	9.0 (7)
Arthralgia	9.0 (7)
Development of autoimmune antibodies (e.g., antinuclear antibodies, anti-dsDNA antibodies)	5.1 (4)
Other	2.6 (2)
Profound anemia	1.3 (1)
Oncologic process	0 (0)
Neurologic event (e.g., neuritis, neuropathy)	0 (0)

78 respondents.